profit from every $100 of sales.
$0$100
Quoin Pharmaceuticals
$3.91+6.99% today
-56.7% in 1 year
1-year low $3.251-year high $22.30
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Quoin Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$15.8 million of profit last year.
SalesProfit
Quoin Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Quoin Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Quoin Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -9 | -9 | -10 | -16 | |
| -9 | -9 | -9 | -16 | |
| -9 | -9 | -9 | -16 | |
| -1,638.23 | -337.47 | -66.85 | -14.80 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 14 | 12 | 16 | 20 |
| Cash | 3 | 2 | 4 | 4 |
| Total debt | – | – | – | – |
| Total liabilities | 7 | 7 | 7 | 7 |
| 7 | 6 | 9 | 13 | |
| 0 | 0 | 0 | 1 | |
| -92.4% | -130.8% | -81.8% | -98.1% | |
| -126.7% | -153.4% | -97.4% | -120.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -8 | -8 | -14 | |
| 0 | – | – | – | |
| -9 | -8 | -8 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 1.9×
- –
- –
- –
- -72,179.2%
- -84.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -168.7%
- -752.9%
- -292.6%
- -108.3%
- -168.7%
- –
Growth
- –
- –
- −172,236.3%
- –
- +408.5%
Financial health
- -0.2×
- 0.00
- 0.0%
- –
- 2.87
- 2.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.77 | -1.80 | +1.7% |
| Mar 26, 2026 | -14.80 | -6.42 | −130.5% |
| Nov 6, 2025 | -6.71 | -6.36 | −5.5% |
| Aug 7, 2025 | -6.28 | -6.83 | +8.1% |
| May 13, 2025 | -6.50 | -3.85 | −68.8% |
| Mar 13, 2025 | -12.24 | -0.50 | −2,348.0% |
| Nov 7, 2024 | -16.43 | -15.38 | −6.8% |
| Aug 8, 2024 | -13.64 | -26.22 | +48.0% |
News
Quoin Pharmaceuticals GAAP EPS of -$1.90 misses by $0.29Seeking Alpha · Aug 14, 2026The newest story we have is from Aug 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
53No pass
Philip Fisher
43No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
33No pass
Terry Smith
30No pass
Questions about Quoin Pharmaceuticals
Is Quoin Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Quoin Pharmaceuticals AI analysis
What does Quoin Pharmaceuticals do?
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It is in Biotechnology.
Does Quoin Pharmaceuticals pay a dividend?
No. Quoin Pharmaceuticals does not pay a dividend at the moment.
Is Quoin Pharmaceuticals stock halal?
Questionable. Quoin Pharmaceuticals sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Quoin Pharmaceuticals stock done over the past year?
Down 56.7% over the past twelve months, to $3.91. It traded between $3.25 and $22.30 and is 82.5% below its high.
Who are Quoin Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Quoin Pharmaceuticals's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.